Skip to content
Targeting New Pathways in Alopecia Areata: The Role of JAK Inhibitors(ID: i818a)
*
1.
How many years have you been in practice?
(Required.)
>21
11-20
1-10
<1
*
2.
How many patients with AA do you manage per week?
(Required.)
1 to 10
11 to 25
26 to 50
I am not directly involved in patient care
*
3.
Please select the option that best describes your practice setting.
(Required.)
Academic medical center
Community hospital or medical center
VA, DOD, or other government
Managed care
Research
Pharmaceutical industry
*
4.
After participating in this activity, how confident are you identifying patients with AA in your practice?
(Required.)
Very confident
Confident
Neutral
Little confidence
No confidence
*
5.
After participating in this activity, how confident are you treating patients with AA in your practice?
(Required.)
Very confident
Confident
Neutral
Little confidence
No confidence
*
6.
How committed are you to making changes in your practice based on your participation in this activity?
(Required.)
Very committed
Committed
Neutral
Not committed
I do not plan to make changes
If not committed or do not plan to make changes, please indicate reason
*
7.
After participating in this activity, which of the following domains do you plan to assess in patients with AA in your practice? Please select all that apply.
(Required.)
Physical signs/symptoms (scalp, skin, nail, hair, irritation, etc)
Emotional impacts
Psychological impacts
Relationship impacts
Social/lifestyle impacts
*
8.
Which of the following best describes the impact of this activity on your performance?
(Required.)
I gained new strategies/skills/information I can apply to my area of practice
I need more information before I can change my practice
My practice is already consistent with the information presented
This activity will not change my practice
*
9.
Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.
(Required.)
Improved knowledge of AA pathophysiology and epidemiology
Better ability to empathize with patients due to increased understanding of the burden on patients with AA
Increased use of diagnostic criteria in order to more accurately diagnose patients with AA
Improved ability to individualize patient management according to consensus recommendations
Better able to recognize patients in need of systemic therapy
Greater understanding of current and emerging therapies and their pathophysiology
Making a more informed decision when deciding on treatment
*
10.
What barriers do you see to making changes in your practice? Please select all that apply.
(Required.)
Lack of knowledge regarding evidence-based strategies
Lack of convincing evidence to warrant change
Lack of time/resources to consider change
Insurance, reimbursement or legal issues
Conflicting guidelines or evidence
Patient compliance and/or patient resource barriers
Other (please explain)
*
11.
Please rate your level of agreement by checking the appropriate rating.
After participating in today’s activity, I am now better able to:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Discuss the epidemiology of AA and the impact of this disease on patient QOL
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Understand the clinical manifestations of AA to improve evaluation of disease severity
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Employ strategies to individualize treatment for patients with AA
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Summarize the pathophysiology of AA
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
12.
Please rate your level of agreement by checking the appropriate rating.
Brett King, MD, PhD, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the Material
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided Commercial Bias
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
13.
Please rate your level of agreement by checking the appropriate rating.
Brittany Craiglow, MD, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the material
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided commercial bias
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
14.
Please rate your level of agreement by checking the appropriate rating.
Sergio Vañó Galván, MD, PhD, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the material
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided commercial bias
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
15.
Please rate your level of agreement by checking the appropriate rating.
The content presented:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Enhanced my current knowledge base
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Addressed my most pressing questions
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Promoted improvements or quality in health care
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Was scientifically rigorous and evidence based
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided commercial bias or influence
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
16.
As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?
17.
Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities on AA:
18.
If you indicated that you perceived commercial bias or influence, please describe: